Unknown

Dataset Information

0

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer.

ABSTRACT: Panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is currently approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC) in combination with chemotherapy in first- and second-line and as monotherapy in chemorefractory patients. This review will provide an overview of main efficacy data on panitumumab from its early development up to latest evidences, including novel perspectives on predictive biomarkers of anti-EGFRs efficacy and mechanisms of secondary resistance. Quality of life (QoL) related issues and panitumumab safety profile will be addressed as well.

SUBMITTER: Battaglin F 

PROVIDER: S-EPMC6607986 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The impact of panitumumab treatment on survival and quality of life in patients with <i>RAS</i> wild-type metastatic colorectal cancer.

Battaglin Francesca F   Puccini Alberto A   Ahcene Djaballah Selma S   Lenz Heinz-Josef HJ  

Cancer management and research 20190628

Panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is currently approved for the treatment of <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC) in combination with chemotherapy in first- and second-line and as monotherapy in chemorefractory patients. This review will provide an overview of main efficacy data on panitumumab from its early development up to latest evidences, including novel perspectives on predictive biomarkers of  ...[more]

Similar Datasets

Unknown Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
| S-EPMC8176979 | biostudies-literature
Unknown Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial.
| S-EPMC5070244 | biostudies-literature
Unknown Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials.
| S-EPMC5010834 | biostudies-literature
Unknown The impact of hepatic and renal function on panitumumab exposures in patients with metastatic RAS wild-type colorectal cancer.
| S-EPMC8367910 | biostudies-literature
Unknown Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
| S-EPMC6613306 | biostudies-literature
Unknown Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients.
| S-EPMC6030389 | biostudies-literature
Unknown Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.
| S-EPMC6738356 | biostudies-literature
Unknown Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.
| S-EPMC5794806 | biostudies-other
Unknown FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
| S-EPMC8018298 | biostudies-literature
Unknown Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status.
| S-EPMC4419154 | biostudies-literature